JP2010513224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513224A5 JP2010513224A5 JP2009524246A JP2009524246A JP2010513224A5 JP 2010513224 A5 JP2010513224 A5 JP 2010513224A5 JP 2009524246 A JP2009524246 A JP 2009524246A JP 2009524246 A JP2009524246 A JP 2009524246A JP 2010513224 A5 JP2010513224 A5 JP 2010513224A5
- Authority
- JP
- Japan
- Prior art keywords
- phenoxy
- propyl
- diphenylmethyl
- group
- substituents selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- VZKQWUSMUDKQQO-UHFFFAOYSA-N 2-[3-[3-(5-benzhydryl-2-oxopyridin-1-yl)propyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(CCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 VZKQWUSMUDKQQO-UHFFFAOYSA-N 0.000 description 4
- -1 methylene -O - Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- AROMICDCRVKJNE-UHFFFAOYSA-N 2-[4-[3-(5-benzhydryl-2-oxopyridin-1-yl)propyl]indol-1-yl]acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1CCCN(C(C=C1)=O)C=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AROMICDCRVKJNE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- KTSBJLUEVCOILP-NRFANRHFSA-N (2s)-2-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 KTSBJLUEVCOILP-NRFANRHFSA-N 0.000 description 1
- NQUJSSMIVNNWJZ-NRFANRHFSA-N (2s)-2-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propylsulfanyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(SCCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 NQUJSSMIVNNWJZ-NRFANRHFSA-N 0.000 description 1
- ZVCYAALGOUJJSF-UHFFFAOYSA-N 4-[3-[2-(3-benzhydryl-6-oxopyridazin-1-yl)ethoxy]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(OCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 ZVCYAALGOUJJSF-UHFFFAOYSA-N 0.000 description 1
- PZGHUBPVYKMTOV-UHFFFAOYSA-N 4-[3-[2-(3-benzhydryl-6-oxopyridazin-1-yl)ethylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 PZGHUBPVYKMTOV-UHFFFAOYSA-N 0.000 description 1
- DFWFRBMZNISVLY-UHFFFAOYSA-N 4-[3-[2-(5-benzhydryl-2-oxopyridin-1-yl)ethylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 DFWFRBMZNISVLY-UHFFFAOYSA-N 0.000 description 1
- SOLKEOGYJUBIEE-UHFFFAOYSA-N 4-[3-[3-(3-benzhydryl-6-oxo-4,5-dihydropyridazin-1-yl)propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(CCC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 SOLKEOGYJUBIEE-UHFFFAOYSA-N 0.000 description 1
- VMMHBVUKRFYWDE-UHFFFAOYSA-N 4-[3-[3-(3-benzhydryl-6-oxopyridazin-1-yl)propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 VMMHBVUKRFYWDE-UHFFFAOYSA-N 0.000 description 1
- ZFOMKUZFVBUCAJ-UHFFFAOYSA-N 4-[3-[3-(5-benzhydryl-2-oxopyridin-1-yl)propylsulfanyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(SCCCN2C(C=CC(=C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=O)=C1 ZFOMKUZFVBUCAJ-UHFFFAOYSA-N 0.000 description 1
- ZSKWGHAKUVYLSD-UHFFFAOYSA-N 4-[3-[3-[3-[bis(4-fluorophenyl)methyl]-6-oxopyridazin-1-yl]propyl]-4-fluorophenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C(F)C(CCCN2C(C=CC(=N2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 ZSKWGHAKUVYLSD-UHFFFAOYSA-N 0.000 description 1
- HZUXMWPXCOEQBS-UHFFFAOYSA-N 4-[3-[3-[3-[bis(4-fluorophenyl)methyl]-6-oxopyridazin-1-yl]propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=N2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 HZUXMWPXCOEQBS-UHFFFAOYSA-N 0.000 description 1
- UZMUEHXLTUQZII-UHFFFAOYSA-N 4-[3-[3-[5-[bis(4-fluorophenyl)methyl]-2-oxopyridin-1-yl]propyl]-4-fluorophenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C(F)C(CCCN2C(C=CC(=C2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 UZMUEHXLTUQZII-UHFFFAOYSA-N 0.000 description 1
- STLJKWYMPVPQBD-UHFFFAOYSA-N 4-[3-[3-[5-[bis(4-fluorophenyl)methyl]-2-oxopyridin-1-yl]propyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCN2C(C=CC(=C2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=O)=C1 STLJKWYMPVPQBD-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87001406P | 2006-12-14 | 2006-12-14 | |
| US60/870,014 | 2006-12-14 | ||
| PCT/JP2007/074475 WO2008072784A1 (en) | 2006-12-14 | 2007-12-13 | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513224A JP2010513224A (ja) | 2010-04-30 |
| JP2010513224A5 true JP2010513224A5 (https=) | 2011-01-20 |
| JP5278318B2 JP5278318B2 (ja) | 2013-09-04 |
Family
ID=39322513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524246A Expired - Fee Related JP5278318B2 (ja) | 2006-12-14 | 2007-12-13 | Ｃｒｔｈ２拮抗剤および抗アレルギー剤として有用な多環酸化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8273745B2 (https=) |
| EP (1) | EP2094662B1 (https=) |
| JP (1) | JP5278318B2 (https=) |
| KR (1) | KR20090096690A (https=) |
| CN (2) | CN101636386A (https=) |
| AR (1) | AR064346A1 (https=) |
| AT (1) | ATE553084T1 (https=) |
| CA (1) | CA2672601A1 (https=) |
| ES (1) | ES2383239T3 (https=) |
| MX (1) | MX2009006312A (https=) |
| PL (1) | PL2094662T3 (https=) |
| PT (1) | PT2094662E (https=) |
| TW (1) | TW200848036A (https=) |
| WO (1) | WO2008072784A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008219166B2 (en) * | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| EP2590944B1 (en) | 2010-07-05 | 2015-09-30 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| JP6097765B2 (ja) | 2011-12-21 | 2017-03-15 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| US10005728B2 (en) | 2013-08-28 | 2018-06-26 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| WO2015148854A1 (en) | 2014-03-27 | 2015-10-01 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| CN105353095B (zh) * | 2015-11-16 | 2017-10-20 | 华南农业大学 | 一种西地那非及其结构类似物的免疫检测方法 |
| JPWO2017104728A1 (ja) * | 2015-12-16 | 2018-11-29 | 幸久 村田 | 食物アレルギー治療薬 |
| WO2017126635A1 (ja) * | 2016-01-22 | 2017-07-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| BR112018067775B1 (pt) | 2016-03-04 | 2024-02-15 | Vanderbilt University | Compostos inibidores de mcl-1 indol substituídos, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos |
| US11608320B2 (en) | 2020-02-02 | 2023-03-21 | Kuwait University | Oxazolidinone hydroxamic acid derivatives |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024393A1 (en) | 1994-03-10 | 1995-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Naphthalene derivatives as prostaglandin i2 agonists |
| EP0781266A1 (de) * | 1994-09-10 | 1997-07-02 | Basf Aktiengesellschaft | Phenylessigsäurealkylester |
| AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
| WO2000069810A1 (en) * | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US20050070529A1 (en) | 2001-02-12 | 2005-03-31 | Merk Pantent Gmbh | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| EP1550461A1 (en) * | 2002-06-26 | 2005-07-06 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| JP4691988B2 (ja) * | 2002-10-03 | 2011-06-01 | 小野薬品工業株式会社 | Ｌｐａ受容体拮抗剤 |
| BRPI0511676A (pt) | 2004-05-29 | 2008-01-08 | 7Tm Pharma As | uso medicinal de ligandos receptores |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
-
2007
- 2007-12-13 ES ES07859872T patent/ES2383239T3/es active Active
- 2007-12-13 EP EP07859872A patent/EP2094662B1/en not_active Not-in-force
- 2007-12-13 CA CA002672601A patent/CA2672601A1/en not_active Abandoned
- 2007-12-13 WO PCT/JP2007/074475 patent/WO2008072784A1/en not_active Ceased
- 2007-12-13 PL PL07859872T patent/PL2094662T3/pl unknown
- 2007-12-13 AR ARP070105614A patent/AR064346A1/es unknown
- 2007-12-13 KR KR1020097008871A patent/KR20090096690A/ko not_active Withdrawn
- 2007-12-13 AT AT07859872T patent/ATE553084T1/de active
- 2007-12-13 US US12/518,280 patent/US8273745B2/en not_active Expired - Fee Related
- 2007-12-13 MX MX2009006312A patent/MX2009006312A/es active IP Right Grant
- 2007-12-13 TW TW096147687A patent/TW200848036A/zh unknown
- 2007-12-13 CN CN200780046458A patent/CN101636386A/zh active Pending
- 2007-12-13 CN CN2011102832598A patent/CN102442941A/zh active Pending
- 2007-12-13 JP JP2009524246A patent/JP5278318B2/ja not_active Expired - Fee Related
- 2007-12-13 PT PT07859872T patent/PT2094662E/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513224A5 (https=) | ||
| JP2018135343A5 (https=) | ||
| JP2009501198A5 (https=) | ||
| JP2010503688A5 (https=) | ||
| JP2012255002A5 (https=) | ||
| JP2009543799A5 (https=) | ||
| JP2009532417A5 (https=) | ||
| JP2010155827A5 (https=) | ||
| JP2015512931A5 (https=) | ||
| JP2010116404A5 (https=) | ||
| JP2013526520A5 (https=) | ||
| JP2008516968A5 (https=) | ||
| JP2006506425A5 (https=) | ||
| RU2011147374A (ru) | Диамидные соединения, обладающие активностью антагониста мускаринового рецептора и активностью агониста в2 адренергического рецептора | |
| JP2011519854A5 (https=) | ||
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| JP2009527501A5 (https=) | ||
| ME02297B (me) | Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora | |
| JP2012530758A5 (https=) | ||
| JP2007519721A5 (https=) | ||
| JP2011527345A5 (https=) | ||
| JP2004533450A5 (https=) | ||
| JP2013542980A5 (https=) | ||
| JP2009541260A5 (https=) | ||
| JP2012526082A5 (https=) |